• Wed. May 22nd, 2024

Grace Science LLC and Andelyn Biosciences Inc.: A Groundbreaking Partnership to Treat NGLY1 Deficiency

BySamantha Nguyen

Mar 25, 2024
Andelyn Biosciences Collaborates with Grace Science to Enhance GS-100

Grace Science LLC has partnered with Andelyn Biosciences Inc. to tech transfer and manufacture GS-100, a suspension process AAV NGLY1 gene therapy for Phase I/II/III clinical trial material for the treatment of NGLY1 Deficiency. This partnership aims to maximize program efficiency, support the ongoing clinical trial, and accelerate the critical therapy to patients suffering from NGLY1 Deficiency, a serious, life-threatening disease with no approved therapy that causes debilitating symptoms.

In the partnership, Andelyn will utilize Grace’s expertise in late-stage manufacturing and commercial readiness to accelerate their manufacturing timelines. Matt Niloff, Chief Commercial Officer at Andelyn Biosciences, emphasized the strong collaboration and customer-centric focus shared by both companies, providing confidence and hope for the success of the GS-100 program.

Matt Wilsey, CEO and Co-Founder of Grace Science, expressed excitement about the partnership, stating that Andelyn’s expertise in AAV gene therapy manufacturing will ensure that NGLY1 patients have access to safe, high-quality drug products for their clinical trial and beyond. The partnership between Andelyn Biosciences and Grace Science aims to bring hope and relief to patients suffering from NGLY1 Deficiency through the development and manufacturing of GS-100.

By Samantha Nguyen

As a content writer at newsskio.com, I weave words to craft compelling narratives that captivate readers and bring stories to life. With a keen eye for detail and a passion for storytelling, I strive to create engaging and informative content that resonates with our audience. Whether I'm delving into the latest news trends or exploring unique angles on various topics, my goal is to deliver quality content that informs, entertains, and inspires. Join me on this journey as we uncover the news stories that matter most.

Leave a Reply